Business Wire: Roche Announces Partner Ipsens Taspoglutide meet its primary endpoint in a phase III of clinical importance. . .
BUSINESS WIRE: Ipsens Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in a Key Phase III Clinical …
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
Read more on vwd.de
About admin
I am a pharmacist in ubonratana hospital for ten years.
This entry was posted in
Neuropathy Product and tagged
Announces,
Business,
Clinical,
endpoint,
importance.,
Ipsens,
meet,
Partner,
Phase,
primary,
Roche,
Taspoglutide,
Wire. Bookmark the
permalink.
